150 related articles for article (PubMed ID: 25354675)
1. Cancer charity demands extension of drug fund despite criticisms it is unfair.
Limb M
BMJ; 2014 Oct; 349():g6507. PubMed ID: 25354675
[No Abstract] [Full Text] [Related]
2. Pfizer to make palbociclib temporarily free on NHS.
Burki TK
Lancet Oncol; 2017 Jun; 18(6):e309. PubMed ID: 28506556
[No Abstract] [Full Text] [Related]
3. Most drugs paid for by £1.27bn Cancer Drugs Fund had no "meaningful benefit".
Cohen D
BMJ; 2017 Apr; 357():j2097. PubMed ID: 28455308
[No Abstract] [Full Text] [Related]
4. Associations Between Industry Sponsorship and Results of Cost-effectiveness Analyses of Drugs Used in Breast Cancer Treatment.
Lane JD; Friedberg MW; Bennett CL
JAMA Oncol; 2016 Feb; 2(2):274-6. PubMed ID: 26658959
[No Abstract] [Full Text] [Related]
5. Adjuvant trastuzumab for breast cancer: the other side of the coin.
Gopalakrishnan S; Linnane J
BMJ; 2005 Nov; 331(7526):1202-3. PubMed ID: 16293846
[No Abstract] [Full Text] [Related]
6. Pfizer makes breast cancer drug free while NICE decides its future.
Kmietowicz Z
BMJ; 2017 May; 357():j2225. PubMed ID: 28483771
[No Abstract] [Full Text] [Related]
7. British clinic is allowed to deny medicine; decision on cost has broad impact.
Lyall S
N Y Times Web; 2006 Feb; ():A10. PubMed ID: 16514743
[No Abstract] [Full Text] [Related]
8. UK Cancer Drugs Fund to reassess 42 agents.
Cagney H
Lancet Oncol; 2015 Jan; 16(1):e8. PubMed ID: 25638560
[No Abstract] [Full Text] [Related]
9. Genentech caps cost of cancer drug for some patients.
Pollack A
N Y Times Web; 2006 Oct; ():C2. PubMed ID: 17061339
[No Abstract] [Full Text] [Related]
10. Patient commentary: the current model has failed.
Robertson E
BMJ; 2017 Oct; 359():j4568. PubMed ID: 28978615
[No Abstract] [Full Text] [Related]
11. Pharmaceutical funding decisions must balance therapeutic innovation, opportunity costs and patient equity.
Ragupathy R; Jameson M
N Z Med J; 2016 Aug; 129(1440):22-4. PubMed ID: 27538036
[No Abstract] [Full Text] [Related]
12. Cancer drugs dropped from 'unsustainable' fund list.
Nurs Stand; 2015 Sep; 30(4):10. PubMed ID: 26394942
[No Abstract] [Full Text] [Related]
13. Court backs Briton's right to a costly drug.
Lyall S
N Y Times Web; 2006 Apr; ():A3. PubMed ID: 16649282
[No Abstract] [Full Text] [Related]
14. [Pharmacoeconomic aspects of breast cancer management].
Kolbin AS; Zagorodnikova KA
Vopr Onkol; 2011; 57(5):604-8. PubMed ID: 22238930
[No Abstract] [Full Text] [Related]
15. BIO 2006 Annual International Convention. The expanding biotech industry of France.
Zarkowska T
IDrugs; 2006 Jun; 9(6):383-5. PubMed ID: 16752302
[No Abstract] [Full Text] [Related]
16. Careful use of science to advance the debate on the UK Cancer Drugs Fund.
Lakdawalla DN; Jena AB; Doctor JN
JAMA; 2014 Jan; 311(1):25-6. PubMed ID: 24381964
[No Abstract] [Full Text] [Related]
17. Which way now for the Cancer Drugs Fund?
Jack A
BMJ; 2014 Sep; 349():g5524. PubMed ID: 25204283
[No Abstract] [Full Text] [Related]
18. Cancer drugs fund receives boost but will no longer fund "overpriced" drugs.
Hawkes N
BMJ; 2014 Sep; 349():g5382. PubMed ID: 25180006
[No Abstract] [Full Text] [Related]
19. New Cancer Drugs Fund is flawed without NICE reform, says Roche.
Hawkes N
BMJ; 2016 Jul; 354():i4216. PubMed ID: 27473207
[No Abstract] [Full Text] [Related]
20. India spurns cancer patents.
Hayden EC
Nature; 2013 Aug; 500(7462):266. PubMed ID: 23955214
[No Abstract] [Full Text] [Related]
[Next] [New Search]
